Healthcare Industry News: Glucose Monitor
News Release - May 12, 2009
Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes
Roche announces wide array of ACCU-CHEK programs centered around Behavior Change through Patient Engagement (SM), including tools for better self-care.INDIANAPOLIS, May 12 -- (Healthcare Sales & Marketing Network) -- Roche, the maker of ACCU-CHEK blood Glucose Monitoring systems and insulin pumps, announced today its long-term commitment to tackle the growing epidemic of diabetes by its Behavior Change through Patient Engagement (SM) program - a wide array of educational programs and tools that promote more effective self-care.
"As the world leader in diabetes diagnostics, we have a responsibility to provide solutions that overcome a critical gap in diabetes management," said Head of Roche Diabetes Care North America Luc Vierstraete. "Traditional diabetes management tends to focus on telling people with diabetes what to do but that, by itself, doesn't necessarily fully engage patients. Our initiative, Behavior Change through Patient Engagement, is all about helping patients take an active role in their diabetes self-care. We know that keeping patients engaged and focused on self-care is critical to long-term success and better outcomes. We are so committed to this effort, we have already invested more than $14 million toward this initiative and will continue to do so."
Roche's Behavior Change through Patient Engagement program offers:
- Coaching skills for healthcare professionals to help achieve breakthroughs in engagement of patients;
- Free patient education programs to help adults, children and teens make self-management easier; and
- Easy tools that help patients discover that the actions they take every day matters - understanding how things like changes in therapy, foods or activities affect their blood glucose.
"Diabetes is a difficult, frustrating disease," said Roche Diabetes Care Medical Director Dr. Andreas Stuhr. "Our Behavior Change program helps healthcare professionals address things like diabetes burnout and other psychological barriers to effective self-care. In addition, we have devised unique and powerful tools to help patients discover that change is worthwhile and achievable."
New educational programs and tools within the Behavior Change through Patient Engagement will continue to be rolled out throughout the year. Meanwhile, existing programs have been further enhanced to fully complement the Behavior Change program.
"We are confident that, together, we can change the future of people who have diabetes," Vierstraete added. "That core belief - that behavior change is worthwhile and achievable - is essential and Roche is committed to helping provide the foundation needed for lasting change."
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood Glucose Monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management - from blood Glucose Monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.
For more information, please visit accu-chek.com.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R & D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us.
All trademarks used or mentioned in this release are protected by law.
Source: Roche Group
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(k) Clearance, Offering a Fast and Raliable Way to Predict the Risk of Developing Severe PreeclampsiaRoche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
